Monopar Therapeutics Bolsa (NASDAQ: MNPR)

Últimas noticias sobre Monopar Therapeutics (NASDAQ:MNPR) Bolsa

MONOPAR THERAPEUTICS INC

Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Monopar Therapeutics Inc

Oil may have spiked on Middle East tensions, but JPMorgan is keeping its cool — and <a href="https://www.benzinga.com/topic/oil">its crude forecast</a> in check. 
In its latest note, the firm reiterates a base case for Brent in the low-to-mid $60s through 2025 and flat at $60 in 2026, brushing aside geopolitical fears as largely priced in.
In fact, JPM pegs Brent&#8217;s fair value at $66, suggesting the commodity sports a $10/bbl geopolitical premium when tensions escalate.
<h2 class="wp-block-heading">Why JPMorgan Isn't Buying The Oil Rally</h2>
JPMorgan has three reasons to stay calm:
<ul class="wp-block-list">
<li>First, an all-out attack on Iran could push oil to $120 and U.S. inflation to 5% &#8211; but the bank sees just a 7% chance of that happening.</li>
<li>Second, the closure of the Strait of Hormuz &#8211; though a nightmare scenario for oil &#8211; would be economic self-sabotage for Iran, which sells most of its crude to China.</li>
<li>Third, the Gulf nations simply can't afford a war right now; economic diversification plans like Saudi's Vision 2030 require peace, not petroleum-fueled chaos.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/commodities/25/06/45948096/exxon-mobil-chevron-occidental-petroleum-in-focus-as-expert-says-us-economy-is-far-less-sensitive-to-an-oil-shock-amid-israel-iran-conflict">Exxon Mobil, Chevron, Occidental Petroleum In Focus As Expert Says &#8216;US Economy Is Far Less Sensitive To An Oil Shock&#8217; Amid Israel-Iran Conflict</a>
<h2 class="wp-block-heading">3 Energy Stock Picks With Good Upside</h2>
But for stock pickers, here's where it gets interesting: JPMorgan analysts also ran an $80 WTI upside case to identify E&amp;Ps with the most leverage to higher oil—and the results are eye-popping.
Leading the charge?
<ul class="wp-block-list">
<li>Civitas Resources Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>): 35% upside to $45</li>
<li>SM Energy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SM#NYSE">SM</a>): 24% upside to $35</li>
<li>Talos Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>): 18% upside to $11</li>
</ul>
These aren't just headline-grabbing gains. In the $80 WTI scenario, these names are expected to post industry-leading FCF-to-enterprise value yields — with Talos hitting 40.7%, SM at 37.1%, and Civitas at 31.2% in 2027, per JPMorgan&#8217;s estimates.
Even with muted oil outlook, these companies stand out for their capital efficiency and torque to price moves. If oil does break higher — or simply stays more resilient than feared &#8211; these small-to-mid-cap E&amp;Ps could handily outperform.
JPMorgan may not be bullish on crude, but it's still spotting high-conviction upside in energy equities. Investors willing to stomach the volatility might find more bang for their buck in these overlooked oil stocks.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/06/45930753/stock-of-the-day-exxon-mobil-breaks-out">Stock Of The Day: Exxon Mobil Breaks Out</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Commodities

Markets

Analyst Ratings

Trading Ideas

CIVI

TALO

JPMorgan Calls For Calm Amid Crude Spike, Flags 3 Energy Stocks With Upto 35% Upside

Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) has outperformed the market over the past 5 years by 4.34% on an annualized basis producing an average annual return of 18.68%. Currently, Encompass Health has a market capitalization of $12.20 billion. 
Buying $1000 In EHC: If an investor had bought $1000 of EHC stock 5 years ago, it would be worth $2,319.05 today based on a price of $120.92 for EHC at the time of writing.
<h3>Encompass Health's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750088713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Here's How Much You Would Have Made Owning Encompass Health Stock In The Last 5 Years

U.S. retail sales for May are expected to post a sharp monthly decline, potentially reinforcing concerns that tariff headlines and economic uncertainty are starting <a href="https://www.benzinga.com/news/econ-s">to pinch consumer spending. </a>
That would mark the second monthly drop in 2025 after January's 0.9% plunge. Monthly declines in retail sales have been rare over the past two years, with only five months showing negative prints.
A fresh pullback—particularly at the start of the second quarter, following an already negative first quarter—could signal that deeper cracks are forming in the U.S. consumer landscape.
<h3 class="wp-block-heading">Retail Sales Look Weak Again—Here's What's Coming</h3>
The median Wall Street economist expects the Bureau of Economic Analysis to report a 0.7% decline in May retail sales Tuesday morning at 8:30 a.m. ET. 
Bank of America is calling for a 0.6% drop. More importantly, they expect the "control group," the slice of sales that actually matters for GDP calculations, to come in flat.
"We expect a soft retail sales report for May," said Adhyta Bhave, economist at Bank of America, in a report last week.
Bank of America's internal credit card data shows that spending was particularly weak in areas like home improvement, groceries and general merchandise.
&#8220;Total card spending per household dropped 0.7% month-over-month on a seasonally adjusted basis,&#8221; the investment bank stated. 
&#8220;If&nbsp;our forecast of a&nbsp;flat print on&nbsp;retail sales ex-autos in&nbsp;May&nbsp;proves&nbsp;correct,&nbsp;the&nbsp;3-month average growth rate would&nbsp;tick down,&#8221; Bhave said. 
<h3 class="wp-block-heading">Are Tariffs To Blame?</h3>
The weakness in consumer spending follows a turbulent period in U.S. trade policy, but Bank of America data suggests that the average household didn't significantly alter its behavior in response to key events—such as the April 2 tariff announcement or the partial trade deal with China on May 12.
The picture changes when looking at high-income households. Wealthier Americans appeared far more responsive to trade developments, particularly when it came to electronics.
&#8220;Electronics have been very sensitive to the news&#8230; We find that the top 5% and top 1% income cohorts&nbsp;increased their online electronics purchases&nbsp;immediately&nbsp;after&nbsp;the April 9 escalation of China tariffs, likely to get ahead of the tariffs,&#8221; Bhave said. 
That pattern repeated among the top 1% following the May 12 U.S.-China agreement.
<h3 class="wp-block-heading">Could The Market React Like It Did in February?</h3>
Back in mid-February, a weak January retail report helped spark a nasty sell-off. 
The S&amp;P 500 lost 0.4% the week January&#8217;s retail data came out and shed 7.8% over the next month. At the time, fears of a recession were back on the table, fueled by President Donald Trump's tough talks on trade.
Both consumer and tech stocks entered a period of weakness. The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) fell 14% over that 30-day stretch following Feb. 14. The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) wasn't spared either, losing 10%.
<h3 class="wp-block-heading">So… Will It Happen Again?</h3>
Maybe not. There are three things working in the market's favor right now.
First, Trump has since put a 90-day pause on reciprocal tariffs, which has taken some of the heat out of trade fears. 
Second, inflation is cooling. Two softer-than-expected CPI reports last week bolstered investor bets on the Fed cutting rates later this year.
Third, on Monday, the geopolitical front took a positive turn. Iran reportedly signaled a desire for de-escalation in fighting with Israel and expressed openness to renegotiating a nuclear deal with the United States. This development pushed oil prices lower, easing energy cost concerns while boosting investor appetite for riskier assets.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45944853/rate-cut-odds-50-50-amid-israel-iran-conflict-says-jerome-powells-ex-advisor-jon-faust">Rate Cut Odds &#8217;50/50&#8242; Amid Israel-Iran Conflict, Says Jerome Powell&#8217;s Ex-Advisor Jon Faust </a></li>
</ul>
 Photo: Hryshchyshen Serhii/Shutterstock

Equities

Macro Economic Events

Sector ETFs

Econ #s

Economics

Federal Reserve

ETFs

Select Sector SPDR-Consumer Discretionary

Retail Sales Face Key Tariff Test: How Could Markets React To Weaker Spending?

William Blair analyst Cristopher Kennedy downgrades Cantaloupe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTLP#NASDAQ">CTLP</a>) from Outperform to Market Perform.

Downgrades

CTLP

William Blair Downgrades Cantaloupe to Market Perform

<a href="https://www.youtube.com/watch?v=N6fLHx_dTfk" title="https://www.youtube.com/watch?v=N6fLHx_dTfk">https://www.youtube.com/watch?v=N6fLHx_dTfk</a>

Politics

Global

General

Trump At G7 Says 'Wouldn't Mind' China Joining G7

Morgan Stanley analyst Vikram Purohit maintains Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) with a Equal-Weight and lowers the price target from $8 to $5.

Price Target

RXRX

Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Lowers Price Target to $5

<a href="https://www.youtube.com/watch?v=N6fLHx_dTfk">https://www.youtube.com/watch?v=N6fLHx_dTfk</a>
&nbsp;

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Trump At G7 Says Iranians Want To Talk About De-escalation; Iran Is Not Winning This War; They Should Talk Before It's Too Late

Trump At G7 Says Trade Deal With Canada Is Achievable, But Both Parties Have To Agree; Going To Talk About Trade And Many Other Things;

Morgan Stanley analyst Matthew Cost initiates coverage on MNTN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNTN#NYSE">MNTN</a>) with a Equal-Weight rating and announces Price Target of $20.

Initiation

MNTN

Morgan Stanley Initiates Coverage On MNTN with Equal-Weight Rating, Announces Price Target of $20

<a href="https://x.com/jenniferjjacobs/status/1934634526178762910?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/jenniferjjacobs/status/1934634526178762910?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>
&nbsp;

CBS News Senior White House Reporter Jennifer Jacobs Posts On X "NEWS: President Trump does NOT intend to sign the G7 statement on Israel-Iran, US officials tell @CBSNews"

Morgan Stanley analyst Craig Hettenbach initiates coverage on Hinge Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HNGE#NYSE">HNGE</a>) with a Overweight rating and announces Price Target of $46.

HNGE

Morgan Stanley Initiates Coverage On Hinge Health with Overweight Rating, Announces Price Target of $46

Canaccord Genuity analyst Tania Armstrong-Whitworth initiates coverage on Eupraxia Pharmaceuticals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EPRX#TSX">EPRX</a>) with a Speculative Buy rating and announces Price Target of C$9.

TSX:EPRX

Canaccord Genuity Initiates Coverage On Eupraxia Pharmaceuticals with Speculative Buy Rating, Announces Price Target of C$9

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and maintains $50 price target.

Reiteration

CLDX

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $50 Price Target

Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) explored commercializing its <a target="_blank" href="https://www.benzinga.com/topic/chip-stocks" rel="noreferrer noopener">advanced 2-nanometer process</a> using gate-all-around (GAA) technology in the second half of 2025.
South Korean rival Samsung Electronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) is also looking to launch its own 2nm process by 2025 to narrow the gap with Taiwan Semiconductor, the Chosun Daily <a target="_blank" href="https://www.chosun.com/english/industry-en/2025/06/16/CSTCW3TPMZBRLDIYILHFY7BRAQ/" rel="noreferrer noopener">reported</a> on Monday.
Samsung was the first to implement GAA in mass production with its 3nm chips in 2022.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45859582" rel="noreferrer noopener">Nvidia Supplier Taiwan Semiconductor Posts 40% Topline Growth In May, Stock Surges</a>
According to the report, the Taiwanese contract chipmaker will start 2nm production simultaneously at its Baoshan and Kaohsiung facilities within Taiwan&#8217;s Hsinchu Science Park.
Taiwan Semiconductor&#8217;s 2nm yield is reportedly stable at around 60% to 70%.
<h2 class="wp-block-heading">Why Does It Matter</h2>
2nm (2 nanometers): In semiconductor terms, it refers to the &#8220;manufacturing process.&#8221; A smaller nanometer number generally indicates more advanced technology, allowing for smaller transistors, higher transistor density (more transistors in the same area), improved performance, and lower power consumption. The 2nm process is at the cutting edge of chip manufacturing.
Achieving 60-70% yield for a brand-new, highly complex, bleeding-edge process like 2nm is considered a very positive sign during the R&amp;D phase.
A yield of 70% or higher (and ideally much higher for mature processes) is desired for profitable mass production.
<h2 class="wp-block-heading">Who Wants To Buy 2nm Chips?</h2>
Apple Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) upcoming&nbsp;iPhone 18&nbsp;lineup <a target="_blank" href="https://www.benzinga.com/25/03/44453733/apples-iphone-18-to-get-massive-boost-with-2nm-a20-chiptsmcs-yields-surge-past-70-says-top-analyst" rel="noreferrer noopener">will likely feature</a> Taiwan Semiconductor&#8217;s&nbsp;2nm A20 chip, according to supply chain analyst Ming-Chi Kuo.
Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) has also tapped its <a target="_blank" href="https://www.benzinga.com/media/25/04/44962945/intel-taps-taiwan-semiconductor-for-advanced-2nm-process-for-ai-powered-chips-report" rel="noreferrer noopener">long-term supplier</a>,&nbsp;Taiwan Semiconductor, for its&nbsp;advanced 2nm process. Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) is also a client of Taiwan Semiconductor&#8217;s 2nm process.
Taiwan Semiconductor reported <a target="_blank" href="https://www.benzinga.com/25/04/44857887/taiwan-semiconductor-q1-surges-41-in-sales-boosted-by-ai-chip-demand-expanded-margins" rel="noreferrer noopener">first-quarter net sales</a> of $25.53 billion (839.25 billion New Taiwanese Dollars), up 41.6% year over year and topping the analyst consensus estimate of $23.92 billion. However, net sales declined&nbsp;3.4% quarter over quarter.
Net income and earnings per share were $361.56 billion New Taiwanese Dollars and 13.94 New Taiwanese Dollars per share (or $2.12), topping the&nbsp;analyst consensus of $1.82.
Taiwan Semiconductor&nbsp;guided second-quarter&nbsp;2025 revenue of $28.4 billion to $29.2 billion, versus the $26.79&nbsp;billion analyst estimate.&nbsp;
Price Action: TSM stock is trading higher by 2.56% to $216.52 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45945838/adobe-to-help-brands-win-the-ai-search-game-with-new-llm-optimizer" target="_blank" rel="noreferrer noopener">Adobe To Help Brands Win The AI Search Game With New LLM Optimizer</a></li>
</ul>
Photo by wakamatsu via Shutterstock

Movers

Tech

Media

AAPL

INTC

SSNLF

Taiwan Semiconductor Eyes Rollout Of 2nm Advanced Tech Chips This Year

Lake Street analyst Ben Haynor assumes Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) with a Buy rating and announces Price Target of $18.

ATEC

Lake Street Assumes Alphatec Holdings at Buy, Announces Price Target of $18

United States Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) has outperformed the market over the past 5 years by 32.2% on an annualized basis producing an average annual return of 46.57%. Currently, United States Steel has a market capitalization of $12.42 billion. 
Buying $1000 In X: If an investor had bought $1000 of X stock 5 years ago, it would be worth $6,731.29 today based on a price of $54.86 for X at the time of writing.
<h3>United States Steel's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750087814_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning United States Steel Stock In The Last 5 Years

Deutsche Bank analyst Matthew Niknam upgrades Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from Hold to Buy and raises the price target from $65 to $73.

Upgrades

CSCO

Deutsche Bank Upgrades Cisco Systems to Buy, Raises Price Target to $73

Trump Media and Technology Group, the parent company of Truth Social, filed an S-1 registration statement with the U.S. Securities and Exchange Commission to launch the Truth Social Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) ETF, B.T., allocating 75% of its assets to Bitcoin and 25% to Ethereum. 
The <a href="https://www.globenewswire.com/news-release/2025/06/16/3099847/0/en/Trump-Media-Files-Registration-Statement-for-Bitcoin-and-Ethereum-ETF.html">filing </a>marks a significant step in the company's expansion into cryptocurrency investment products, aligning with its broader push into financial services through its Truth.Fi platform.
Truth Social, launched in 2022 as a social media platform to counter perceived Big Tech censorship, has grown to 13 million users, emphasizing free expression. 
Also Read: <a href="https://www.benzinga.com/crypto/25/06/45951049/justin-suns-tron-plans-us-public-listing-amid-deepening-ties-with-trump-family-and-crypto-political-shift">Justin Sun&#8217;s Tron Plans US Public Listing Amid Deepening Ties With Trump Family And Crypto-Political Shift</a>
The company also operates Truth+, a streaming service with family-friendly content, and is developing Truth.Fi, a fintech brand focused on "America First" investment vehicles. 
The proposed ETF, sponsored by Yorkville America Digital, will hold Bitcoin and Ether directly, aiming to track their price performance, with Crypto.com serving as the custodian, prime execution agent, and liquidity provider.
"The ETF will hold Bitcoin and Ether directly, with 75% of its assets invested in Bitcoin and 25% in Ether, and offer its shares (the ‘Shares') to investors, aiming to reflect the price performance of Bitcoin and Ether," the company stated in its press release. 
The ETF's shares are set to list on NYSE Arca, pending SEC approval of the S-1 registration and a Form 19b-4 filing, with a decision expected by January 29, 2026, at the latest.
The filing follows Trump Media's recent $2.3 billion Bitcoin treasury <a href="https://finance.yahoo.com/news/trump-media-plunges-13-despite-131347819.html">deal</a>, reflecting its deepening commitment to digital assets. 
"Crypto.com will act as the ETF's exclusive Bitcoin and Ether custodian and prime execution agent, as well as staking and liquidity provider," the press release noted. 
The move comes amid a favorable regulatory shift under SEC Chair Paul Atkins, who has prioritized easing crypto regulations, though the filing includes cautions about risks, including potential regulatory changes under the Trump administration.
Trump Media, majority-owned by President Donald Trump through a trust managed by Donald Trump Jr., has faced scrutiny for potential conflicts of interest. 
The ETF enters a competitive market dominated by BlackRock's iShares Bitcoin Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>), with nearly $70 billion in assets. 
The company emphasized that "the proposed offering will be made only by means of a prospectus" and that shares cannot be sold until the registration statement is effective.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45949930/strategy-acquires-1-05-billion-in-bitcoin-pushes-holdings-to-592100-btc-with-19-1-yield-in-2025">Strategy Acquires $1.05 Billion In Bitcoin, Pushes Holdings To 592,100 BTC With 19.1% Yield In 2025</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

IBIT

Truth Social's Bitcoin And Ethereum ETF Filing With SEC Aims For 75% BTC, 25% ETH

<a href="https://wccftech.com/apple-watch-with-blood-glucose-monitoring-arriving-in-2027/" title="https://wccftech.com/apple-watch-with-blood-glucose-monitoring-arriving-in-2027/">https://wccftech.com/apple-watch-with-blood-glucose-monitoring-arriving-in-2027/</a>

Biotech

"Apple Watch With Blood Glucose Monitoring Could Arrive In Two Years, According To A Product Launch Roadmap Laid Out By Analyst, No Word If 'Ultra' Variant Will Obtain The Feature" - WCCFtech

Craig-Hallum analyst Chase Knickerbocker initiates coverage on Neuraxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NRXS#AMEX">NRXS</a>) with a Buy rating and announces Price Target of $7.

Comments

Monopar Therapeutics

Noticias

Últimas noticias sobre Monopar Therapeutics (NASDAQ:MNPR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL